ClinicalTrials.gg
CompletedNCT01924533Updated Mar 22, 2024Results posted

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

A Phase 3 interventional study of Olaparib and Paclitaxel in Gastric Cancer, sponsored by AstraZeneca. Completed at 57 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
525
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Stomach Neoplasms by AstraZeneca — 10 open to participants now, 18 under way, 3 of them phase 3. Stomach Neoplasms · AstraZeneca.

Enrollment
6th of 27
525 · median 124
Started
2013
the only one that year
Phase 3
4 of 30
2 open now
Registered
7th of 30
by date

Among the 30 studies in Stomach Neoplasms by AstraZeneca, this one is the 6th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 3, and was the 7th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

10 of the 30 studies in Stomach Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Stomach Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy. Patients will be from China, Japan , Korea and Taiwan.

Read the detailed description

A randomized, double-blinded, multicentre phase III study to access the efficacy and safety of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in Asian patients with advanced gastric cancer (including gastro-oesophageal junction) who have progressed following first line therapy.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced gastric cancer (including GEJ) that has progressed following therapy.
  • Patients must be ≥18 years of age. Age ≥20 if Japanese
  • Provision of tumour sample (from either a resection or ).
  • At least one lesion (measurable and/or non-measurable) that can be accurately assessed by imaging (CT/MRI) at baseline and following up visits.

Exclusion criteria

Exclusion Criteria:

  • More than one prior chemotherapy regimen (except for /neoadjuvant chemotherapy with more than 6 month wash out period) for the treatment of gastric cancer in the advanced setting.
  • Any previous treatment with a Polyadenosine 5'-diphosphoribose [poly-(ADP-ribose)] polymerisation (PARP) inhibitor, including olaparib.
  • Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥5 years.
  • Human Epidermalgrowth Factor Receptor-2 () positive patients.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
525 participants (actual)

Study arms

  • Experimental
    Olaparib+ paclitaxel

    olaparib + paclitaxel

    Drug: Olaparib · Drug: Paclitaxel

  • Placebo comparator
    Placebo+paclitaxel

    placebo+ paclitaxel

    Drug: Paclitaxel · Drug: Placebo

Interventions

  • Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.

  • IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.

  • DrugPlacebo

    Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time from the date of randomization until death due to any cause

    Time frame: Survival contact from the date of randomization and then every 8 weeks following objective disease progression and in the 7 days following OS Data Cut off (DCO); Time point(s) at which outcome measure is assessed up to 4 years

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time from randomization until the date of objective radiological disease progression according to RECIST (v1.1) or death by any cause in the absence of progression. Objective progression is defined as at least a 20% increase in the sum of the diameters of the target lesions (compared to previous minimum sum) or an overall non-target lesion assessment of progression or a new lesion.

    Time frame: Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years

  2. Number of Patients With Objective Response.

    Number of patients with objective response. Per RECIST 1.1, complete response (CR) is disappearance of all target lesions since baseline; partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Overall Response = CR + PR.

    Time frame: Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years

  3. Number of Patients Objective Response

    Number of patients with objective response. Per RECIST 1.1, complete response (CR) is disappearance of all target lesions since baseline; partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Overall Response = CR + PR.

    Time frame: Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years

  4. Number of Patients With Deterioration of Health Related Quality of Life (HRQoL) as Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 Item Module (QLQ-C30) Global HRQoL Scale

    Number of patients with a clinically important deterioration in the global HRQoL score or death by any cause in the absence of a clincially meaningful symptom deterioration

    Time frame: Pre-treatment , Day 29 and then every 4 weeks until discontinuation, assessed up to 3 years

  5. Time to Response

    Time from randomization to the first onset of a confirmed objective tumour response

    Time frame: Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years

  6. Duration of Response

    Time from the first documentation of CR/PR until the date of progression, or the last evaluable RECIST assessment for patients taht do not progress or progress after two or more missed visits

    Time frame: Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years

07

Results

Posted Nov 7, 2018

Participant flow

Participant flow — Overall Study
MilestoneOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Started263262
Completed7457
Not completed189205
Withdrew: Death181200
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject73
Withdrew: Other eligibility criteria11

Outcome measures

PrimaryOverall Survival

Time from the date of randomization until death due to any cause

Time frame:
Survival contact from the date of randomization and then every 8 weeks following objective disease progression and in the 7 days following OS Data Cut off (DCO); Time point(s) at which outcome measure is assessed up to 4 years
Reported as:
Number · participants
Overall Survival
participantsOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Overall Survival8262
Statistical analysis
  • Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2 · Cox proportional hazards model · p = 0.0262 · Hazard ratio (hr): 0.79 · 97.5% CI 0.63 to 1.00
PrimaryOverall Survival

Time from the date of randomization until death due to any cause

Time frame:
Survival contact from the date of randomization and then every 8 weeks following objective disease progression and in the 7 days following OS Data Cut off (DCO); Time point(s) at which outcome measure is assessed up to 4 years
Reported as:
Number · participants
Overall Survival
participantsOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Overall Survival1911
Statistical analysis
  • Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2 · Cox proportional hazards model · p = 0.2458 · Hazard ratio (hr): 0.73 · 97.5% CI 0.40 to 1.34
SecondaryProgression-Free Survival (PFS)

Time from randomization until the date of objective radiological disease progression according to RECIST (v1.1) or death by any cause in the absence of progression. Objective progression is defined as at least a 20% increase in the sum of the diameters of the target lesions (compared to previous minimum sum) or an overall non-target lesion assessment of progression or a new lesion.

Time frame:
Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Reported as:
Number · participants
Progression-Free Survival (PFS)
participantsOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Progression-Free Survival (PFS)4729
Statistical analysis
  • Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2 · Cox proportional hazards model · p = 0.0645 · Hazard ratio (hr): 0.84 · 97.5% CI 0.67 to 1.04
SecondaryProgression-Free Survival (PFS)

Time from randomization until the date of objective radiological disease progression according to RECIST (v1.1) or death by any cause in the absence of progression. Objective progression is defined as at least a 20% increase in the sum of the diameters of the target lesions (compared to previous minimum sum) or an overall non-target lesion assessment of progression or a new lesion.

Time frame:
Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Reported as:
Number · participants
Progression-Free Survival (PFS)
participantsOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Progression-Free Survival (PFS)117
Statistical analysis
  • Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2 · Cox proportional hazards model · p = 0.2199 · Hazard ratio (hr): 0.74 · 97.5% CI 0.42 to 1.29
SecondaryNumber of Patients With Objective Response.

Number of patients with objective response. Per RECIST 1.1, complete response (CR) is disappearance of all target lesions since baseline; partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Overall Response = CR + PR.

Time frame:
Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Reported as:
Number · participants
Number of Patients With Objective Response.
participantsOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Number of Patients With Objective Response.4428
Statistical analysis
  • Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2 · Regression, Logistic · p = 0.0548 · Odds ratio (or): 1.69 · 97.5% CI 0.92 to 3.17
SecondaryNumber of Patients Objective Response

Number of patients with objective response. Per RECIST 1.1, complete response (CR) is disappearance of all target lesions since baseline; partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Overall Response = CR + PR.

Time frame:
Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Reported as:
Number · participants
Number of Patients Objective Response
participantsOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Number of Patients Objective Response125
Statistical analysis
  • Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2 · Regression, Logistic · p = 0.0309 · Odds ratio (or): 4.24 · 97.5% CI 0.95 to 23.23
SecondaryNumber of Patients With Deterioration of Health Related Quality of Life (HRQoL) as Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 Item Module (QLQ-C30) Global HRQoL Scale

Number of patients with a clinically important deterioration in the global HRQoL score or death by any cause in the absence of a clincially meaningful symptom deterioration

Time frame:
Pre-treatment , Day 29 and then every 4 weeks until discontinuation, assessed up to 3 years
Reported as:
Number · participants
Number of Patients With Deterioration of Health Related Quality of Life (HRQoL) as Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 Item Module (QLQ-C30) Global HRQoL Scale
participantsOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Number of Patients With Deterioration of Health Related Quality of Life (HRQoL) as Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 Item Module (QLQ-C30) Global HRQoL Scale160177
Statistical analysis
  • Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2 · Cox proportional hazards model · p = 0.0716 · Hazard ratio (hr): 0.82 · 97.5% CI 0.64 to 1.05
SecondaryNumber of Patients With Deterioration of Health Related Quality of Life (HRQoL) as Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 Item Module (QLQ-C30) Global HRQoL Scale

Number of patients with a clinically important deterioration in the global HRQoL score or death by any cause in the absence of a clincially meaningful symptom deterioration

Time frame:
Pre-treatment , Day 29 and then every 4 weeks until discontinuation, assessed up to 3 years
Reported as:
Number · participants
Number of Patients With Deterioration of Health Related Quality of Life (HRQoL) as Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 Item Module (QLQ-C30) Global HRQoL Scale
participantsOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Number of Patients With Deterioration of Health Related Quality of Life (HRQoL) as Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 Item Module (QLQ-C30) Global HRQoL Scale2933
Statistical analysis
  • Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2 · Cox proportional hazards model · p = 0.0927 · Hazard ratio (hr): 0.63 · 97.5% CI 0.34 to 1.16
SecondaryTime to Response

Time from randomization to the first onset of a confirmed objective tumour response

Time frame:
Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Reported as:
Median · days
Time to Response
daysOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Time to Response57.0 (54.5 to 64.0)57.0 (56.0 to 111.5)
SecondaryTime to Response

Time from randomization to the first onset of a confirmed objective tumour response

Time frame:
Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Reported as:
Median · days
Time to Response
daysOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Time to Response57.5 (57.0 to 113.0)57.0 (55.0 to 58.0)
SecondaryDuration of Response

Time from the first documentation of CR/PR until the date of progression, or the last evaluable RECIST assessment for patients taht do not progress or progress after two or more missed visits

Time frame:
Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Reported as:
Median · days
Duration of Response
daysOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Duration of Response166.0 (89.0 to 218.0)64.0 (54.0 to 186.0)
SecondaryDuration of Response

Time from the first documentation of CR/PR until the date of progression, or the last evaluable RECIST assessment for patients taht do not progress or progress after two or more missed visits

Time frame:
Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Reported as:
Median · days
Duration of Response
daysOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Duration of Response171.0 (124.0 to 350.0)108.0 (57.0 to 113.0)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2181/263 (68.8%)92/262 (35.1%)257/262 (98.1%)
Placebo Tablets bd + Paclitaxel 80 mg/m^2200/262 (76.3%)65/259 (25.1%)253/259 (97.7%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
Bone marrow disorderBlood and lymphatic system disorders6/2623/259
PneumoniaInfections and infestations6/2624/259
Febrile neutropeniaBlood and lymphatic system disorders5/2622/259
GranulocytopeniaBlood and lymphatic system disorders5/2622/259
LeukopeniaBlood and lymphatic system disorders5/2620/259
IleusGastrointestinal disorders4/2624/259
VomitingGastrointestinal disorders4/2624/259
PyrexiaGeneral disorders4/2624/259
Abdominal painGastrointestinal disorders4/2623/259
Intestinal obstructionGastrointestinal disorders3/2621/259
Most frequent other events
Showing 10 of 40
Most frequent other events
EventOlaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2
NeutropeniaBlood and lymphatic system disorders122/262108/259
AlopeciaSkin and subcutaneous tissue disorders112/262116/259
AnaemiaBlood and lymphatic system disorders99/26262/259
Decreased appetiteMetabolism and nutrition disorders86/26269/259
NauseaGastrointestinal disorders75/26263/259
LeukopeniaBlood and lymphatic system disorders71/26257/259
Neutrophil count decreasedInvestigations67/26238/259
DiarrhoeaGastrointestinal disorders66/26251/259
White blood cell count decreasedInvestigations60/26248/259
FatigueGeneral disorders48/26252/259

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2Total
Mean57.1 ± 11.9057.3 ± 11.1457.2 ± 11.52
Age, Continuous
Age, Continuous(Years)Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2Total
Mean57.0 ± 12.0860.9 ± 9.9058.9 ± 11.18
Age, Customized
Age, Customized(Participants)Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2Total
>=18 - <506864132
>=50 - <65115128243
>=658070150
Age, Customized
Age, Customized(Participants)Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2Total
>=18 - <5012719
>=50 - <65222446
>=65141529
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2Total
Female8977166
Male174185359
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2Total
Not Hispanic Or Latino263262525
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2Total
Asian263262525
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2Placebo Tablets bd + Paclitaxel 80 mg/m^2Total
Not Hispanic or Latino484694

4 further baseline measures are reported on the registry.

08

Study locations

57 sites
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100071, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Bengbu, 233060, China
  • Research Site
    Changchun, 130000, China
  • Research Site
    Changsha, 410005, China
  • Research Site
    Changsha, 410011, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chengdu, 610083, China
  • Research Site
    Fuzhou, 350014, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310016, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210002, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200092, China
  • Research Site
    Urumqi, 830000, China
  • Research Site
    Wanzhou, 404000, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Chiba-shi, 260-8717, Japan
  • Research Site
    Chuo-ku, 104-0045, Japan
  • Research Site
    Fukuoka-shi, 811-1395, Japan
  • Research Site
    Kasama-shi, 309-1793, Japan
  • Research Site
    Kawasaki-shi, 216-8511, Japan
  • Research Site
    Kitaadachi-gun, 362-0806, Japan
  • Research Site
    Koto-ku, 135-8550, Japan
  • Research Site
    Matsuyama-shi, 791-0280, Japan
  • Research Site
    Nagoya-shi, 464-8681, Japan
  • Research Site
    Sapporo-shi, 003-0804, Japan
  • Research Site
    Sapporo-shi, 060-8648, Japan
  • Research Site
    Takatsuki-shi, 569-8686, Japan
  • Research Site
    Utsunomiya-shi, 320-0834, Japan
  • Research Site
    Yokohama-shi, 241-8515, Japan
  • Research Site
    Anyang-si, 431-070, Korea, Republic of
  • Research Site
    Daegu, 42415, Korea, Republic of
  • Research Site
    Hwasun-gun, 58128, Korea, Republic of
  • Research Site
    Jeonju-si, 561-712, Korea, Republic of
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 02841, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 06273, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Seoul, 156-707, Korea, Republic of
  • Research Site
    Seoul, 6351, Korea, Republic of
  • Research Site
    Kaohsiung Hsien, 83342, Taiwan
  • Research Site
    Taichung, Taiwan
  • Research Site
    Tainan, 704, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1637-1651. doi: 10.1016/S1470-2045(17)30682-4. Epub 2017 Nov 2. PubMed 29103871 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Apr 2016, 31 months.

Results were first posted in Nov 2018, 2 years 7 months after primary completion.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 31 months is below that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2013
First posted
Aug 16, 2013
StartActual
Sep 3, 2013
Primary completionActual
Apr 4, 2016
CompletionActual
Mar 27, 2023
Results first posted
Nov 7, 2018
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01924533
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 16, 2013
Start date
Sep 3, 2013
Primary completion
Apr 4, 2016
Completion
Mar 27, 2023
Results posted
Nov 7, 2018
Last update
Mar 22, 2024

Study contacts

Yung-Jue Bang, MD
principal investigator · Seoul National University, College of Medicine and Cancer Research Institute, Republic of Korea

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion